The DIABLO Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted cell population derived from the human Raji B lymphocyte line, targeting the DIABLO gene encoding the pro-apoptotic mitochondrial protein SMAC. This polyclonal knockout model provides a heterogeneous pool of cells with loss-of-function mutations in DIABLO, enabling robust investigation of apoptosis signaling in a B-cell malignancy context without clonal selection artifacts. The cell population is designed for researchers studying the intrinsic apoptotic pathway and resistance mechanisms in lymphoma.
Raji cells are a well-established human Burkitt lymphoma-derived B lymphocyte line widely employed in cancer biology, immunology, and drug discovery. Of lymphoid origin, these suspension cells serve as a model for B-cell lymphomas and leukemias, characterized by their rapid proliferation and distinct molecular features. The Raji background provides a relevant platform to assess the role of apoptosis regulators in lymphocyte survival and therapeutic response, particularly within the context of hematological malignancies.
DIABLO (also known as SMAC) functions as a critical endogenous antagonist of inhibitor of apoptosis proteins (IAPs). Upon apoptotic stimuli, DIABLO is released from the mitochondrial intermembrane space alongside cytochrome c and directly binds to IAPs such as XIAP, cIAP1, and cIAP2, which normally suppress caspase-3, -7, and -9 activity. DIABLO neutralization of IAPs permits caspase activation and execution of cell death. Upstream regulators include p53, BAX, BAK, and caspase-8; interacting partners include XIAP, cIAP1, cIAP2, HTRA2/Omi, and ARTS; and downstream effectors converge on caspases-3, -7, and -9. In the knockout model, sustained IAP activity blocks caspase activation, conferring apoptosis resistance.
In the Raji B-cell lymphoma background, DIABLO loss of function is expected to confer heightened resistance to intrinsic and extrinsic apoptotic signals by sustaining IAP-mediated caspase inhibition. This model recapitulates a mechanism often observed in B-cell malignancies, where IAP overexpression or DIABLO dysfunction contributes to disease progression and drug resistance. It therefore provides a genetically defined system to study apoptosis defects driving lymphoma and to evaluate therapeutic strategies aiming to bypass IAP-dependent survival.
This polyclonal DIABLO knockout cell population enables a variety of research applications, from mechanistic apoptosis studies and modeling of chemoresistance in B-cell cancers to screening of IAP antagonists such as SMAC mimetics. Key assays include Western blotting for DIABLO, XIAP, and cleaved caspases; flow cytometry for annexin V and active caspase-3; cell viability assays (MTT, ATP-based); co-immunoprecipitation to analyze DIABLO-IAP interactions; RT-qPCR; and drug sensitivity testing. For additional details, please contact Ascent Research.
